bacTRL-Spike / Symvivo - LARVOL DELTA

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Symvivo Corporation | Active, not recruiting ➔ Completed | Trial primary completion date: May 2022 ➔ Aug 2022

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Symvivo Corporation | Trial completion date: Feb 2022 ➔ Sep 2022 | Trial primary completion date: Feb 2022 ➔ May 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: Symvivo Corporation; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Symvivo Corporation; N=12 ➔ 24

Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease

First Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike, an Oral COVID-19 Vaccine Candidate (Businesswire) - "Symvivo Corporation...today announced the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19....Preliminary data are anticipated in early 2021. Unlike traditional vaccines that are delivered by intramuscular injection, bacTRL-Spike™ is taken orally, providing the potential for individuals to self-administer the vaccine rather than requiring a trained medical professional."

P1 data • Trial status • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Symvivo Corporation; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Symvivo Corporation; N=112 ➔ 12; Initiation date: Jul 2020 ➔ Oct 2020; Trial primary completion date: Aug 2021 ➔ Dec 2021

Clinical • Enrollment change • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1; N=112; Not yet recruiting; Sponsor: Symvivo Corporation; N=84 ➔ 112

Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (clinicaltrials.gov) - P1; N=84; Not yet recruiting; Sponsor: Symvivo Corporation

Clinical • New P1 trial